Author

LA Vornik

Observed names: L Vornik, L. A. Vornik, L. Vornik

Institution: The University of Texas MD Anderson Cancer Center

Observed institutions: Northwestern University, Brigham and Women's Hospital, National Institutes of Health, Mayo Clinic, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, University of Alabama, Baylor College of Medicine, Columbia University Irving Medical Center, Tel Aviv Sourasky Medical Center, Sheba Medical Center, Moffitt Cancer Center, GlaxoSmithKline (United States), Dana-Farber Cancer Institute, National Cancer Institute, Weill Cornell Medical Center, Columbia University

OpenAlex ID: A5086467136

Abstract OT2-09-01: Pilot study of denosumab in BRCA1/2 mutation carriers scheduling for risk-reducing salpingo-oophorectomy

2019 · MS Trivedi, G Samimi, et al. · Cancer Research · 2

Abstract OT2-09-02: A phase I dose escalation study of topical bexarotene in women at high risk for breast cancer

2019 · PS Thomas, AB Patel, et al. · Cancer Research · 1

Abstract PS3-01-20: Prospective evaluation of breast mammographic density and biomarker changes induced by 4-hydroxytamoxifen gel application versus placebo to the breast of women at increased risk for breast cancer

2026 · B. K. Arun, G. Gierach, et al. · Clinical Cancer Research

Abstract PD3-07: A phase II pre-surgical trial of lapatinib for the treatment of women with HER2 positive or EGFR positive ductal carcinoma in situ

2019 · PS Thomas, A Contreras, et al. · Cancer Research

Abstract OT3-01-04: VADIS trial: Phase II trial of the nelipepimut-S peptide v accine in women with DCIS of the breast

2017 · EA Mittendorf, G Plitas, et al. · Cancer Research

Phase IB randomized, double-blinded, placebo-controlled, dose-escalation study of polyphenon E in women with a history of hormone receptor-negative breast cancer.

2010 · K. D. Crew, P. Brown, et al. · Journal of Clinical Oncology

Works count: 6

Citation count: 3

H-index: 1

I10-index: